Inovio Pharmaceuticals Inc expected to post a loss of 74 cents a share - Earnings Preview

Inovio Pharmaceuticals

09/05/2025 21:39

Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show no change in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

​LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 74 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $7.50​, above​ its last closing price of $1.82. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.79
-0.84
-0.60
Beat
28.3
Sep. 30 2024
-1.14
-1.15
-0.89
Beat
22.6
Jun. 30 2024
-1.12
-1.10
-1.19
Missed
-8​
Mar. 31 2024
-1.01
-1.00
-1.31
Missed
-30.6
​​Dec. 31 2023
-1.42
-1.27
-1.12
Beat
11.6
Sep. 30 2023
-1.50
-1.52
-1.56
Missed
-2.6​
Jun. 30 2023
-1.81
-1.74
-1.56
Beat
10.3
Mar. 31 2023
-1.76
-1.74
-1.92
Missed
-10.3

This summary was machine generated May 9 at 20:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)